biotech
biotech Articles
Shares of Cerus dropped just after the open of Wednesday’s regular trading session despite a key FDA approval.
Published:
Last Updated:
Celator Pharmaceuticals has announced positive results from its Phase 3 trial of Vyxeos Liposome for Injection in patients with high-risk (secondary) acute myeloid leukemia.
Published:
Last Updated:
Aeglea BioTherapeutics has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
One analyst firm believes the development of abuse-deterrent formulations (ADF) of opioids creates a risk that older non-ADFs may be removed from the market, creating a huge risk and opportunity in...
Published:
Last Updated:
For the most part, Jefferies maintained its list of top companies in the health care sector, but it also made a couple additions and updated its price target information.
Published:
Last Updated:
GW Pharmaceuticals has announced the positive results of the first pivotal Phase 3 study of its investigational medicine Epidiolex for the treatment of Dravet syndrome.
Published:
Last Updated:
24/7 Wall St. has collected three big FDA decisions coming up in March and added some color, along with the trading range and price target.
Published:
Last Updated:
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) scored a win in a late-stage trial for the treatment of rheumatoid arthritis (RA). The company, in conjunction with Sanofi, announced that a Phase 3...
Published:
Last Updated:
Corvus Pharmaceuticals expects to price more than 4 million shares in the range of $15 to $17 apiece in an initial public offering valued up to nearly $92 million.
Published:
Last Updated:
Audentes Therapeutics has amended its filing with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Published:
Last Updated:
The February 29 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
Published:
Last Updated:
With biotechs still way out of favor, investors need to be cautious, as often these companies are dependent on binary data. These three could have positive upcoming data presented.
Published:
Last Updated:
Over the past week, Halozyme Therapeutics and a couple of other biotech companies made impressive runs.
Published:
Last Updated:
Novavax reported disappointing fourth-quarter financial results before the markets opened on Monday.
Published:
Last Updated:
Over the past week, Valeant Pharmaceuticals and a few other biotech companies made impressive runs, due to positive trial results and an FDA meeting.
Published:
Last Updated: